Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2004-11-05
2010-06-01
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C424S085700, C530S351000
Reexamination Certificate
active
07727519
ABSTRACT:
Methods for the treatment of interferon-response disorders by administration of an interferon alone or in combination with adjunctive therapy are described. The invention encompasses providing to a patient both a formulation of an interferon that is suitable for short-term administration and a formulation of an interferon associated with a sustained release delivery system that is suitable for long-term administration. A principal advantage of the method is that responsiveness to treatment can be ascertained with short-term dosimetric techniques using one formulation of an interferon, which permits the appropriate selection of a dose that is both effective and safe for long-term administration using the second formulation.
REFERENCES:
patent: 4211771 (1980-07-01), Witkowski et al.
patent: 4673405 (1987-06-01), Guittard et al.
patent: 4675184 (1987-06-01), Hasegawa et al.
patent: 4695623 (1987-09-01), Stabinsky
patent: 4727138 (1988-02-01), Goeddel et al.
patent: 4762791 (1988-08-01), Goeddel et al.
patent: 4820638 (1989-04-01), Swetly et al.
patent: 4845196 (1989-07-01), Cowling
patent: 4847079 (1989-07-01), Kwan
patent: 4885166 (1989-12-01), Meyer et al.
patent: 4897471 (1990-01-01), Stabinsky
patent: 4915954 (1990-04-01), Ayer et al.
patent: 4917887 (1990-04-01), Hauptmann et al.
patent: 4917895 (1990-04-01), Lee et al.
patent: 4929554 (1990-05-01), Goeddel et al.
patent: 4976966 (1990-12-01), Theeuwes et al.
patent: 5004689 (1991-04-01), Fiers et al.
patent: 5019382 (1991-05-01), Cummins, Jr.
patent: 5112614 (1992-05-01), Magruder et al.
patent: 5120306 (1992-06-01), Gosselin
patent: 5120832 (1992-06-01), Goeddel et al.
patent: 5207752 (1993-05-01), Sorensen et al.
patent: 5221278 (1993-06-01), Linkwitz et al.
patent: 5231176 (1993-07-01), Goeddel et al.
patent: 5318558 (1994-06-01), Linkwitz et al.
patent: 5324280 (1994-06-01), Wong et al.
patent: 5368863 (1994-11-01), Eckenhoff et al.
patent: 5413572 (1995-05-01), Wong et al.
patent: 5429602 (1995-07-01), Hauser
patent: 5443459 (1995-08-01), Wong et al.
patent: 5529914 (1996-06-01), Hubbell et al.
patent: 5543156 (1996-08-01), Roorda et al.
patent: 5574137 (1996-11-01), Gray et al.
patent: 5602010 (1997-02-01), Hauptmann et al.
patent: 5605688 (1997-02-01), Himmler et al.
patent: 5660847 (1997-08-01), Magruder et al.
patent: 5676942 (1997-10-01), Testa et al.
patent: 5690925 (1997-11-01), Gray et al.
patent: 5728396 (1998-03-01), Peery et al.
patent: 5738845 (1998-04-01), Imakawa
patent: 5795779 (1998-08-01), McCormick et al.
patent: 5807876 (1998-09-01), Armistead et al.
patent: 5858746 (1999-01-01), Hubbell et al.
patent: 5906816 (1999-05-01), Soos et al.
patent: 5908621 (1999-06-01), Glue et al.
patent: 5939286 (1999-08-01), Johnson et al.
patent: 5942223 (1999-08-01), Bazer et al.
patent: 5985305 (1999-11-01), Peery et al.
patent: 6007805 (1999-12-01), Foster et al.
patent: 6060450 (2000-05-01), Soos et al.
patent: 6069133 (2000-05-01), Carlo et al.
patent: 6113938 (2000-09-01), Chen et al.
patent: 6129761 (2000-10-01), Hubbell
patent: 6172046 (2001-01-01), Albrecht
patent: 6204022 (2001-03-01), Johnson et al.
patent: 6372218 (2002-04-01), Cummins, Jr.
patent: 6436091 (2002-08-01), Harper et al.
patent: 6472512 (2002-10-01), LaFleur et al.
patent: 6833256 (2004-12-01), Pontzer et al.
patent: 6875748 (2005-04-01), Manthorpe et al.
patent: 7101567 (2006-09-01), Sano et al.
patent: 2004/0225113 (2004-11-01), LaFleur et al.
patent: 0 079 405 (1983-05-01), None
patent: 1 046 399 (2000-10-01), None
patent: 1 084 703 (2001-03-01), None
patent: WO 93/08832 (1993-05-01), None
patent: WO 96/03116 (1996-02-01), None
patent: WO 99/62501 (1999-12-01), None
patent: WO 00/38652 (2000-07-01), None
patent: WO 00/39280 (2000-07-01), None
patent: WO 00/39280 (2000-07-01), None
patent: WO 00/40273 (2000-07-01), None
patent: WO 00/40273 (2000-07-01), None
patent: WO 00/40273 (2000-07-01), None
patent: WO 00/40273 (2000-07-01), None
patent: WO 02/36072 (2002-05-01), None
patent: WO 03/030923 (2003-04-01), None
Zhang et al. Efficacy observations of different dosages of interferon to treat 150 Hepatitis B carriers. Current Physician. 1997. vol. 2, No. 12, pp. 45-46.
Adolf, G., et al., “Antigenic structure of human interferon ω1 (Interferon αll1): comparison with other human interferons,”J. Gen. Virol. 68(Pt 6):1669-1676 (Jun. 1987).
Adolf, G. et al. “Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) ω1: evidence that IFN- ω1 is a component of human leukocyte IFN,”Virology175(2):410-471 (Apr. 1990).
Adolf, G., et al., “Purification and characterization of natural human interferon ω1,”J. Bio. Chem. 265(16):9290-9295 (Jun. 1990).
Adolf. G., et al., “Human interferon ω1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein,”Biochim. Biophys. Acta108(9):167-174 (Jun. 1991).
Aulitzky, W., “Acute hematologic effects of interferon α, interferon γ, tumor necrosis factor α and Interleukin 2,”Ann. Hemetol. 62(1):25-31 (Feb. 1991).
Balkwill, F. “Interferons,”in Cytokines in Cancer Therapy, Oxford University Press: Oxford, GB (1989).
Balkwill, F., “Interferons,”Lancet1(8646):1060-1063 (May 1989).
Bekkering, F., et al., “Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model,”Hepatology33(2):419-423 (Feb. 2001).
Bolinger, A., et al., “Recombinant interferon γ for treatment of chronic granulomatous disease and other disorders,”Clin. Pharm. 11(10):834-850 (Oct. 1992).
Bonkovsky, H., et al., “Outcomes research in chronic viral hepatitis C: effects of interferon therapy,”Can. J. Gastroenterol. 14(Supp. B):21B-29B (Jul.-Aug. 2000).
Borden, E., et al., “Second-generation interferons for cancer: clinical targets,”Semin. Cancer Biol. 10(2):125-144 (Apr. 2000).
Condino-Neto, A., “Interferon-γ improves splicing efficiency of CYBB gene transcripts in an interferon responsive variant of chronic granulomatous disease due to a splice site consensus region mutation,”Blood95(11):3548-3554 (Jun. 2000).
Davis, G., et al., “Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C,”Prog. Abstr. 50thAnnu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX, Abstract 570 (Nov. 5-9, 1999).
Di Marco, V., et al., “Combined treatment of relapse of chronic hepatitis C with high-dose α-2B interferon plus ribavirin for 6 or 12 months,”Prog. Abstr. 50thAnnu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX, Abstract 569 (Nov. 5-9, 1999).
Elias, L., et al., “Infusional Interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study,” Cancer 89(3):597-603 (Aug. 2000).
Fang, J., et al., “The impact of baseline liver histology on virologic response to interferon α-2b±ρ ribavirin therapy in patients with chronic hepatitis C,”Prog. Abstr. 50thAnnu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX, Abstract 572 (Nov. 5-9, 1999).
Ferenci, P., et al, “Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C,”Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA, Abstract 977 (May 21-24, 2000).
Fontaine, H., et al., “Recovery from chronic hepatitis C in long-term responders to ribarivin plus interferon α,”Lancet356(9223):41 (Jul. 2000).
Glue, P., et al., “A dose-ranging study of Peg-intron and ribavirin in chronic hepatitis C—safety, efficacy, and virological rationale,”Prog. Abstr. 50thAnnu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX, Abstract 571 (Nov. 5-9, 1999).
Gonzales, H., et al., “Randomized c
Fabian Gary R.
Hissong Bruce D
Intarcia Therapeutics, Inc.
Landsman Robert
McClung Barbara G.
LandOfFree
Method for treating hepatitis C virus with omega interferon does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating hepatitis C virus with omega interferon, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating hepatitis C virus with omega interferon will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4174005